Citations

Clear

4510 citation(s) found for "Scott, C".

Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS)
Al-Samkari, Hanny, Friday, Cassi , Kasthuri, R., Gossage, James R. , Murphy, Charles Griffin, Hountras, Peter, Kirkland, Kristi Jackson, Iyer, Vivek, Prasad, Vikas, Ahluwalia, Vaibhav, Rodriguez-Lopez, Josanna, Conrad, Miles , Hetts, S, Chakinala, Murali M. , Beasley, Melissa, Kirkpatrick, P., Lindquist, Jonathan , Battaile, John T., Lu, An, Parambil, Joseph G. , McCrae, KR, Sheynzon, V., Whitehead, Kevin, Sion, Cassidy, McWilliams, Justin P. , Cusumano, Lucas R. , Trerotola, Scott O. , Chesnutt, Mark S., Kaufman, Claire , Dickey, Melissa Ann, Krock, Nolie, Cottrill, Crystal, Competiello, Tania, Levy, Hara , Clancy, Marianne S. , Henderson, Katharine, Pollak, J., Iyer, Vivek , Al‐Samkari, Hanny , Kasthuri, Raj S. , Al-Samkari, Hanny , Kasthuri, Raj S , Murphy, Charles G , Iyer, Vivek N , Ahluwalia, Vaibhav , Rodriguez-Lopez, Josanna M , Conrad, Miles , Hetts, Steven , Ohliger, Michael , Sisk, Bryan A , Beasley, Melissa A , Lindquist, Jonathan , McCrae, Keith R , Whitehead, Kevin J , Cusumano, Lucas R , Drivas, Theodore G , Kaufman, Claire , Dickey, Melissa , Krock, Nolie , Smith, Karen L. , Kirkland, Kristi, Rodriguez‐Lopez, Josanna , Witkin, Alison S. , Hetts, Steven W. , Sisk, Bryan A. , Lu, An, Whitehead, Kevin J. , Drivas, Theodore G. , Dickey, Melissa , Boyce, Danielle M. , Pollak, Jeffrey

Mayo Clinic

Blood | March 17, 2026 | Volume: 148 | Issue: 4 | Pages: 417-432

10.1182/blood.2026033112 | PMID 41843464 Get It

Abstract Hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant vasculopathy affecting 1 in 5000 individuals, is the second most common inherited bleeding disorder worldwide. Despite this prevalence, comprehensive data on disease manifestations and complications remain limited. To address this gap, the US Congress allocated funding leading to the Comprehensive HHT Outcomes Registry of the United States (CHORUS), a prospective, 15-center longitudinal registry enrolling unselected patients with confirmed HHT. In this initial report, we describe findings from the first 600 participants, with a median age of 53 (range, 0-88) years and 60% female. Despite most participants developing typical HHT manifestations by age 13 years, the majority (63%) were not diagnosed until mid-to-late adulthood. Recurrent spontaneous epistaxis occurred in 95% of participants, chronic gastrointestinal bleeding in 30%, and heavy menstrual bleeding in 35% of postmenarche females, together resulting in moderate-to-severe mucosal bleeding in 76%. Iron deficiency and/or anemia were diagnosed in 68%, with 41% requiring IV iron and 25% requiring red cell transfusions. Serious complications of solid-organ arteriovenous malformations were frequent, including intracranial hemorrhage (3%), pulmonary hemorrhage (2%), venous thromboembolism (7%), arterial thromboembolism (11%), heart failure (7%), and pulmonary hypertension (7%). These data from CHORUS, the first national US registry of its kind, provide reliable, real-world estimates of the incidence, prevalence, and severity of numerous HHT manifestations and complications. HHT has a high burden of moderate-to-severe bleeding, anemia, thrombosis, and major neurologic and cardiopulmonary complications. There is a mean interval between first symptoms and diagnosis of >2 decades, during which substantial, serious, and preventable HHT morbidity, including early intracranial hemorrhage, may occur. This trial was registered at clinicaltrials.gov as NCT06259292.
Germline genetic variants and epilepsy surgery response: individual-participant pooled analysis of 269 patients
Ivaniuk, Alina, Bajaj, Sunanjay , Bosselmann, Christian M, Koh, Hyun Yong, Pestana-Knight, E, Zhang, Xiaoming, Bingaman, William, Najm, Imad, Shah, Manish N., Tandon, N., Allmen, Gretchen Von , Lhatoo, Samden D. , Tatum, William, Freund, Brin , Miller, Kai J. , Wirrell, Elaine, Coryell, J., Schreiber, John, Perry, Scott, Lal, Dennis , Ivaniuk, Alina , Ivaniuk, Alina , Boßelmann, Christian M. , Koh, Hyun Yong , Pestana‐Knight, Elia , Bingaman, William , Najm, Imad , Shah, Manish N. , Tatum, William, Wirrell, Elaine , Fine, Anthony L. , Coryell, Jason , Schreiber, John R. , Perry, Scott

Mayo Clinic

No container title available | March 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.10.26347961 Get It

Abstract Background Genetic testing is increasingly used in presurgical evaluation, but the yield of resection across germline genetic epilepsies remains uncertain. Methods We conducted a systematic review of MEDLINE (PubMed) and Scopus and added cases from three institutional cohorts and the Pediatric Epilepsy Research Consortium (PERC) databases, including individuals with pathogenic/likely pathogenic germline variants besides tuberous sclerosis and neurofibromatosis who underwent resection or laser ablation. Etiologies were grouped into biologically informed categories (GATORopathies, vascular, overgrowth, CNVs, channelopathies, synaptopathies, other). Primary outcome was seizure freedom (Engel I) at last follow-up. Group comparisons used Fisher’s exact and Kruskal–Wallis tests (α=0.05; Bonferroni when applicable). Prespecified sensitivity analyses stratified by lesional status, excluded GATORopathies, and restricted to literature-only cases. Results We included 223 literature cases (64 studies), 35 institutional cases, and 11 PERC cases (n=269). Median follow-up was 24 months (IQR 12–48.0). Seizure freedom was achieved in: vascular disorders 14/19 (73.6%), GATORopathies 79/120 (67.5%), CNVs 18/31 (66.7%), overgrowth 7/13 (53.8%), other 16/25 (41.7%), channelopathies 13/43 (33.3%), and synaptopathies 4/18 (22.2%) (overall p<0.001). Among cases with known imaging, 208/253 (82.2%) had epileptogenic MRI lesions, including 64% of channelopathies and 80% of the synaptopathies. In univariate contrasts (each category vs all others), odds of seizure freedom were higher for vascular disorders (2.66-fold, 95% CI 0.87–9.72) and GATORopathies (2.46-fold, 95% CI 1.46–4.18), and lower for synaptopathies (∼4.2-fold lower, OR 0.24, 95% CI 0.05– 0.78) and channelopathies (∼4.5-fold lower, OR 0.22, 95% CI 0.09–0.48). Direction and magnitude were consistent across prespecified sensitivity analyses (lesional-only, literature-only, exclusion of GATORopathies). Conclusions Resective surgeries can be effective in germline genetic epilepsies, but outcomes vary by pathway. Disorders with discrete, lesional substrates (GATORopathies, vascular) show the highest likelihood of seizure freedom, whereas channelopathies and synaptopathies, despite the presence of MRI lesions, have substantially lower yields even in lesional cases. Prospective, genotype-aware surgical registries with standardized reporting (EEG, imaging, pathology) and time-to-event outcomes are needed to refine the selection of surgical candidates and quantify seizure and non-seizure-related outcomes.
Coronary Endothelial Dysfunction Is Associated With Major Depressive Disorder in Men With Chest Pain and Nonobstructive Coronary Artery Disease
Sara, Jaskanwal D. S., Breitinger, Scott , Rajai, Nazanin , Lerman, Lilach O, Lerman, Amir, Lerman, Amir , Sara, Jaskanwal Deep Singh , Sara, Jaskanwal D S , Lerman, Lilach O , Lerman, Amir , Rajai, Nazanin , Lerman, Lilach O.

Mayo Clinic

Journal of the American Heart Association | March 13, 2026 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/jaha.125.045020 | PMID 41823233 Get It

Background Studies have demonstrated an association between endothelial dysfunction and major depressive disorder (MDD). However, the link between coronary endothelial dysfunction (CED) and an incident diagnosis of MDD across sexes is unclear. Methods Patients with nonobstructive coronary artery disease (stenosis <40%) underwent an invasive assessment of CED. Macrovascular CED was defined as a percentage change in coronary diameter in response to acetylcholine of ≤−10% compared with baseline. Microvascular CED was defined as a percentage change in coronary blood flow in response to acetylcholine of ≤−50% compared with baseline. In the period after the index procedure, patients were followed up for developing a diagnosis of MDD, and logistic regression was performed to assess the association between baseline CED and incident MDD. Results In total, 2280 patients underwent invasive testing for CED. A total of 516 patients (23%) underwent an evaluation for MDD at a date after the index procedure (mean±SD age, 53±12 years; 72% women). A total of 160 (31%) were diagnosed with MDD. The percentage change in coronary diameter in response to acetylcholine was lower in those diagnosed with MDD in all patients (−10.8% versus −5.3%; P =0.008), and in men (−19.0% versus −4.8%; P =0.001). In men, a higher proportion of those with macrovascular CED were diagnosed with MDD compared with those not diagnosed with MDD (59% versus 38%; P =0.035). In multivariable analyses, macrovascular CED was associated with MDD in men (odds ratio: 2.99 [95% CI, 1.26–7.45]; P =0.015). Conclusions Macrovascular CED is significantly associated with incident MDD in men with nonobstructive coronary artery disease. Endothelial dysfunction in the coronary arteries could thus be a helpful biomarker to identify patients at risk of MDD.
From Insight to Action: A National Patient‐Centered Strategic Framework for Improving Reproductive Health Outcomes in Individuals With Congenital Heart Disease
Messmer, Mindi , Gupta, Tripti , D'Souza, Rohan , Russo, Melissa L. , Jackson, Jamie L. , Singh, Kashvi , Salciccioli, Katherine B. , Bravo‐Jaimes, Katia, Abusbeitan, Ayesha, Cortes, Jennifer, Hile, Danielle, Phillippi, Ruth, Leezer, Scott, John, Anitha S. , Bravo‐Jaimes, Katia , D’Souza, Rohan , Russo, Melissa , Bravo-Jaimes, Katia , Kasparian, Nadine A , Abusbeitan, Ayesha , Hile, Danielle , John, Anitha , Jackson, Jamie , Cortes, Jennifer

Mayo Clinic

Journal of the American Heart Association | March 13, 2026 | Volume: 15 | Issue: 6 | Pages: No page available

10.1161/jaha.125.046867 | PMID 41823229 Get It

Background An increasing number of patients with congenital heart disease (CHD) are pursuing pregnancy with the potential for cardiovascular complications. This study aimed to establish patient‐centered national research and care priorities to improve pregnancy‐related outcomes for individuals with CHD. Methods This mixed‐methods study used a modified Stakeholder Engagement in Question Development methodology to systematically identify patient‐centered priorities. Key activities included consortium engagement (phase 1), patient and provider questionnaires (phase 2), and an in‐person facilitated meeting to explore survey results and follow‐up virtual focus groups (phase 3). Reflexive thematic analysis was used to synthesize short‐ and long‐term research priorities (phase 4). Results Three overarching goals emerged: (1) improving access to specialized CHD, cardio‐obstetrics, and mental health care; (2) improving quality and consistency in clinical care; and (3) increasing patient and community engagement. These goals were then expanded into 5 central themes: (1) communication within the health care setting; (2) community engagement; (3) ancillary clinical support; (4) integration of patient‐reported outcomes; and (5) implementation, education, and knowledge mobilization. Short‐term (1–5‐year) goals included expanded telemedicine use, best practice recommendations for multidisciplinary care coordination, and targeted educational resources. Long‐term (5–10‐year) goals included expansion of adult CHD and cardio‐obstetrics programs, integration of mental health services, and advocacy to improve insurance coverage. Conclusions The consortium provided a national, community‐driven prioritization that highlights actionable pathways to improve pregnancy outcomes for people with CHD. Sustained engagement with patients and community partners is essential to achieving durable improvements across cardio‐obstetric care, education, research, and mental health.
Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer
Baratz, Hannah , Hidalgo, C. , Abel, Kathryn M. Van , Wilson, Jessica, Baral, Binav, Bayne, Harry E. Fuentes, Price, Katharine R., Baratz, Hannah Q , Hidalgo, Cecelia, Lester, Scott C. , Fuentes Bayne, Harry E, McGarrah, Patrick W. , Van Abel, Kathryn M , Price, Daniel L. , Routman, David M. , Price, Katharine R., Yin, Linda X.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | March 12, 2026 | Volume: 152 | Issue: 5 | Pages: 490

10.1001/jamaoto.2026.0080 | PMID 41817516 Get It

IMPORTANCE Neoadjuvant chemoimmunotherapy has high rates of pathologic response and improved prognosis among solid tumors. Its role in head and neck squamous cell carcinoma (HNSCC) remains understudied. OBJECTIVE To summarize the efficacy associated with neoadjuvant chemoimmunotherapy regimens in HNSCC and to compare the efficacy associated with neoadjuvant chemoimmunotherapy vs immunotherapy alone in locoregionally advanced resectable HNSCC prior to definitive surgery. DATA SOURCES A librarian-led systematic review was conducted using multiple electronic databases, including Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus, following Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines. Databases were queried from inception to October 2024. STUDY SELECTION Inclusion criteria included prospective interventional trials that have completed accrual, with results published in English. Only trials of resectable, treatment-naive HNSCC were included. Exclusion criteria included lack of reporting on pathologic response or Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 response. DATA EXTRACTION AND SYNTHESIS Two investigators independently conducted title, abstract, and full-text reviews per PRISMA guidelines. Primary outcomes extracted were major pathologic response (MPR) and complete pathologic response (CPR) at surgery and complete response (CR) on imaging by RECIST 1.1. Secondary outcomes included 1-year overall survival (OS) and toxic effects. MAIN OUTCOMES AND MEASURES A meta-analysis was performed using a binary random-effects model to determine the pooled proportion of primary outcomes in the immunotherapy and chemoimmunotherapy groups. Heterogeneity was reported as I 2 . RESULTS A total of 751 patients (502 [77%] male; age range, 27-87 years) across 23 studies were included in the meta-analysis, including 357 patients (47%) who underwent chemoimmunotherapy, 102 patients (14%) who underwent dual-agent immunotherapy, and 292 patients (39%) who underwent single-agent immunotherapy. Pooled rates of MPR plus CPR were 66% (95% CI, 58%-73%; I 2 = 0.59) for chemoimmunotherapy, 18% (95% CI, 6%-29%; I 2 = 0.65) for dual-agent immunotherapy, and 6% (95% CI, 3%-9%; I 2 &amp;lt; 0.01) for single-agent immunotherapy. Across all groups, 1-year OS rates ranged from 88% to 96% for single-agent immunotherapy, 88% to 96% for dual-agent immunotherapy, and 88% to 100% for chemoimmunotherapy. Grade 3 to 5 adverse events were reported in 61 of 210 patients (29%), 2 of 67 patients (3.0%), and 36 of 210 patients (17%) among the reporting studies in the single-agent immunotherapy, dual-agent immunotherapy, and chemoimmunotherapy groups, respectively. CONCLUSIONS AND RELEVANCE These findings suggest that neoadjuvant chemoimmunotherapy regimens were associated with higher pathologic and radiographic response rates compared with immunotherapy alone in locoregionally advanced HNSCC. These results call for phase 3 trials comparing these neoadjuvant regimens head to head.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
Wierda, William G., Brown, Jennifer, Abramson, Jeremy, Bociek, Greg, Boyer, Daniel F. , Cortese, Matthew J , Cripe, Larry D., D’Angelo, Christopher R. , Darnell, Elijah P., Davis, Randall S. , Eradat, Herbert, Esteghamat, Naseem , Fitzgerald, Lindsey , Fletcher, Christopher D., Gaballa, Sameh , Kamdar, Manali, Kipps, Thomas J., Ma, Shuo, Nakhoda, Shazia, Schorr, Andrew, Schuster, Stephen, Seshadri, Madhav, Shanafelt, T., Ujjani, Chaitra, Wagner-Johnston, Nina, Woyach, Jennifer A. , Dwyer, Mary, Sundar, Hema, Shanafelt, Tait D. , Shanafelt, Tait D , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Huntington, Scott F. , Kahl, Brad S. , Kamdar, Manali , Kipps, Thomas J. , Ma, Shuo, Mosse, Claudio A. , Nakhoda, Shazia , Parikh, Sameer A. , Riedell, Peter A. , Seshadri, Madhav , Siddiqi, Tanya , Sitlinger, Andrea Phillips , Thompson, Meghan C , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Dwyer, Mary A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 12, 2026 | Volume: 24 | Issue: 3 | Pages: 68-80

10.6004/jnccn.2026.0012 | PMID 41825137 Get It

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL/SLL and Richter transformation.
Clinical Assessment in Respiratory Care. 5th edition.
Copeman, Scott E

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 51 | Issue: 4 | Pages: 426-427

10.4187/respcare.06510426 Get It

LGG-10. Diffuse leptomeningeal glioneuronal tumor: a comprehensive clinical and molecular analysis
Mikkelsen, Margit , Li, Xiaoyu, Yu, Kaiwen, High, Anthony A. , Tan, Haiyan, Furtado, Larissa V. , Berry, Julia D., Boué, Daniel R. , Chien, Franklin , Dewan, Michael, Hoffman, Lindsey, Kofler, Julia , Larkin, Trisha , May, Adriana , Noun, Dolly , Schwartz, Jonathan, Sheila, Ivanna, Spiller, Susan, Tanak, Ryuma, Robinson, Giles W, Peng, Junmin, Chiang, Jason, Moreira, Daniel, Li, Xiaoyu, Leelatian, Nalin , Bell, Jessica, Coven, Scott L. , Dewan, Michael Christopher , Foster, Jessica , Hoffman, Lindsey M. , Lazow, Margot , Mobley, Bret C. , Posorske, Benjamin , Schwartz, Jonathan , Qaddoumi, Ibrahim A. , Chiang, Jason

Mayo Clinic

Neuro-Oncology Pediatrics | March 12, 2026 | Volume: 1 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuaf001.193 Get It

Abstract Diffuse leptomeningeal glioneuronal tumors (DLGNT) are rare central nervous system tumors. Our understanding of the clinical course, prognostic factors, and optimal treatment strategies remains limited. Histologic, molecular, and clinical data were collected and analyzed for 25 patients with DLGNT reviewed at St. Jude Children’s Research Hospital. The median age at diagnosis was 6 years (11 months-20 years). Nineteen (72%) patients were male. The disease was localized at diagnosis in 12 (48.0%) patients, with most tumors localized in the spinal cord. BRAF fusion was present in 22 (95.6%) of 23 patients who had material for testing. Of 18 patients who had tissue for DNA methylation profiling, 3 (16.7%) matched to DLGNT MC-1, 3 (16.7%) to DLGNT MC-2, and 12 (66.7%) did not match to a DLGNT subclass. Median follow-up was 63 months. Twenty-four (96.0%) patients received adjuvant therapy after initial diagnosis or at progression. Thirty-five cytotoxic chemotherapy and 24 single-agent targeted therapy regimens were used in 22 and 13 patients, respectively. With targeted therapy, 3 (12%) patients had partial responses. Eleven (44.0%) received radiotherapy. Median progression-free survival (PFS) after a patient’s first chemotherapy, targeted therapy, or radiotherapy regimen was 44 months (1-77), 11 months (4-39), and 16.5 months (9-23), respectively. The 5-year PFS was 18.7%±9.2, while the 5-year overall survival (OS) was 82.4%±9.2. The 5-year OS was lower in patients older than 9 years at diagnosis (60.0%±21.9 vs 91.7%±8.0, p = 0.02). Ki67 &gt;4% was associated with worse PFS (0%±0 vs 24.6%±11.9 at 5 years, p = 0.03). Initial disease dissemination (localized vs. disseminated) and 1q gain status do not influence PFS or OS. PFS for DLGNT remains poor across all treatment modalities, including targeted therapies, despite the high frequency of BRAF fusions. Due to its rarity, establishing optimal therapeutic strategies for DLGNT requires additional treatment and outcome data and prospective multi-institutional trials.
Intersectional challenges facing women in radiology and oncology
Carroll, Evelyn F. , Scott-Blagrove, Jade, Viswanathan, Chitra , Obaro, Anu , Carroll, Evelyn, Obaro, Anu E , Iyizoba-Ebozue, Zsuzsanna

Mayo Clinic

British Journal of Radiology | March 9, 2026 | Volume: 99 | Issue: 1180 | Pages: 688-691

10.1093/bjr/tqag038 | PMID 41802167 Get It

Abstract As a group of diverse co-authors working in the fields of clinical radiology and oncology, we have first-hand experience of the systems that impact medical careers. Women remain underrepresented in most spaces and often face a complex set of obstacles exacerbated by additional protected characteristics such as race, disability and sexual orientation. The impact of flexible working and care giving responsibilities on career development as well as leadership opportunities further widens the gap between under- and overrepresented groups. In this commentary we describe the intersectional challenges faced by women in our specialties and the challenge of navigating these spaces to achieve career success. We explore the various forms of discrimination and its impact on representation in medicine. Potential strategies and solutions aimed at promoting a more equitable specialty are also highlighted.